Martinez Damonte V, Pomrenze M, Manning C, Casper C, Wolfden A, Malenka R
Biol Psychiatry. 2022; 93(2):197-208.
PMID: 35961792
PMC: 9976994.
DOI: 10.1016/j.biopsych.2022.06.011.
Huang M, Xu L, Liu J, Huang P, Tan Y, Chen S
Front Aging Neurosci. 2022; 14:828457.
PMID: 35283752
PMC: 8914319.
DOI: 10.3389/fnagi.2022.828457.
Yamane T, Suzui S, Kitaura H, Takahashi-Niki K, Iguchi-Ariga S, Ariga H
PLoS One. 2013; 8(11):e78374.
PMID: 24348900
PMC: 3865339.
DOI: 10.1371/journal.pone.0078374.
Lodge D
Neuropsychopharmacology. 2011; 36(6):1227-36.
PMID: 21307842
PMC: 3079406.
DOI: 10.1038/npp.2011.7.
You Z, Tzschentke T, Brodin E, Wise R
J Neurosci. 1998; 18(16):6492-500.
PMID: 9698337
PMC: 6793204.
Effects of ceruletide on perioral movements and the dopamine receptor-adenylate cyclase system in rats chronically treated with fluphenazine.
Ashizawa T, Saito T, Takahata N
Psychopharmacology (Berl). 1996; 125(3):185-94.
PMID: 8815952
DOI: 10.1007/BF02247327.
Devazepide, a CCKA receptor antagonist, impairs the acquisition of conditioned reward and conditioned activity.
Josselyn S, Franco V, Vaccarino F
Psychopharmacology (Berl). 1996; 123(2):131-43.
PMID: 8741936
DOI: 10.1007/BF02246170.
Effects of ceruletide on the dopamine receptor-adenylate cyclase system in striatum and frontal cortex of rats chronically treated with haloperidol.
Hatta Y, Hatta S, Saito T
Psychopharmacology (Berl). 1993; 110(4):383-9.
PMID: 7870906
DOI: 10.1007/BF02244642.
Total synthesis, purification, and characterization of human [Phe(p-CH2SO 3Na)52, Nle32,53,56, Nal55]-CCK20-58, [Tyr52, Nle32,53,56, Nal55]-CCK-58, and [Phe(p-CH2SO3Na)52, Nle32,53,56, Nal55]-CCK-58.
Miranda M, Craig A, Miller C, Liddle R, Rivier J
J Protein Chem. 1993; 12(5):533-44.
PMID: 7511387
DOI: 10.1007/BF01025118.
Immunohistochemical demonstration of a CCK-like peptide in the nervous system of a marine annelid worm, Nereis diversicolor O.F. Müller.
Engelhardt R, Dhainaut-Courtois N, Tramu G
Cell Tissue Res. 1982; 227(2):401-11.
PMID: 6295633
DOI: 10.1007/BF00210894.
Neuropeptides in dopamine-containing regions of the brain.
Albanese A, Altavista M
Ital J Neurol Sci. 1984; 5(4):391-404.
PMID: 6152262
DOI: 10.1007/BF02042622.
Proceedings of the British Pharmacological Society. London, 17th-19th December, 1984. Abstracts.
Br J Pharmacol. 1985; 84 Suppl:1P-203P.
PMID: 3978323
PMC: 1987318.
Neurotensin and cholecystokinin coexistence within neurons of the ventral mesencephalon: projections to forebrain.
Seroogy K, Mehta A, Fallon J
Exp Brain Res. 1987; 68(2):277-89.
PMID: 3319664
DOI: 10.1007/BF00248793.
A controlled study of Tourette syndrome. VII. Summary: a common genetic disorder causing disinhibition of the limbic system.
Comings D
Am J Hum Genet. 1987; 41(5):839-66.
PMID: 3314491
PMC: 1684345.
Differential effects of proglumide on mesolimbic and nigrostriatal dopamine function.
Csernansky J, Glick S, Mellentin J
Psychopharmacology (Berl). 1987; 91(4):440-4.
PMID: 3108924
DOI: 10.1007/BF00216008.
Effect of ceruletide on tardive dyskinesia: a pilot study of quantitative computer analyses on electromyogram and microvibration.
Nishikawa T, Tanaka M, Tsuda A, Kuwahara H, Koga I, Uchida Y
Psychopharmacology (Berl). 1986; 90(1):5-8.
PMID: 3094061
DOI: 10.1007/BF00172862.
Neuronal cholecystokinin and schizophrenia: pathogenic and therapeutic studies.
Tamminga C, Littman R, Alphs L, Chase T, Thaker G, Wagman A
Psychopharmacology (Berl). 1986; 88(3):387-91.
PMID: 3083460
DOI: 10.1007/BF00180843.
Double blind controlled trials of cholecystokinin octapeptide in neuroleptic-refractory schizophrenia.
Peselow E, Angrist B, Sudilovsky A, Corwin J, Siekierski J, Trent F
Psychopharmacology (Berl). 1987; 91(1):80-4.
PMID: 2881320
DOI: 10.1007/BF00690931.
Computer simulation of the conformational behavior of cholecystokinin fragments: conformational families of sulfated CCK8.
Kreissler M, Pesquer M, Maigret B, Fournie-Zaluski M, Roques B
J Comput Aided Mol Des. 1989; 3(1):85-94.
PMID: 2715797
DOI: 10.1007/BF01590997.
Infusions of cholecystokinin octapeptide into the ventral tegmental area potentiate amphetamine conditioned place preferences.
Pettit H, Mueller K
Psychopharmacology (Berl). 1989; 99(3):423-6.
PMID: 2594910
DOI: 10.1007/BF00445571.
